Industrial Rhamnolipid Market Size & Share 2026-2035

Industrial Rhamnolipid Market Size

The industrial rhamnolipid market was valued at USD 467.8 million in 2025 and is projected to reach USD 950.5 million by 2035, expanding at a CAGR of 8.4% over 2026–2035. The market reaches USD 500.1 million in 2026.

Rhamnolipids are fermentation-derived glycolipid biosurfactants whose rhamnose head group and fatty-acid chains enable surface and interfacial-tension control in aqueous systems. The commercial market includes liquid and powder rhamnolipids across technical, high-purity, and ultra-high-purity grades sold into industrial-scale applications; laboratory quantities below 1 kg, sophorolipids, synthetic surfactants, and captive internal output are excluded. ^{[1]Royal Society of Chemistry (RSC), Rhamnolipid Biosurfactants: Structural Properties and Industrial Applications, rsc.org}

The historic growth rate of 6.7% during 2022–2024 reflected a market still constrained by production economics and qualification cycles. From 2026, the growth profile rests less on discovery-stage interest and more on whether formulators can secure repeatable supply, fit rhamnolipids into existing process equipment, and justify their premium through compliance, performance, or formulation differentiation. Evonik inaugurated a rhamnolipid plant in Slovenská Ľupča, Slovakia, in May 2024, describing it as the first facility to produce these biosurfactants at industrial scale. That event matters because it changes the commercial question from availability alone to application conversion: cleaning, personal care, agriculture, and oilfield customers can progress from evaluation to formulation programs when a scaled supplier establishes a dependable reference point. ^{[2]Evonik Industries AG, World's First Industrial-Scale Rhamnolipid Plant Inaugurated in Slovakia, evonik.com}

The estimate follows demand-side revenue recognized by commercial producers and distributors from end-user purchases. It triangulates the global revenue series against independent type, form, grade, end-use, and regional builds; each framework reconciles to the global total. The value chain begins with sugars and vegetable oils, then moves through microbial fermentation, extraction, purification, formulation, distribution, and end-user deployment. Feedstock and downstream purification remain economically decisive because both determine the premium against petrochemical surfactants.

Key Drivers

Enhanced oil recovery is the market's largest near-term volume engine because oil and gas represented 40.2% of 2025 revenue. Rhamnolipids reduce interfacial tension between oil and water, making them relevant to mobilization in mature reservoirs and to selected drilling-fluid and well-treatment formulations. The International Energy Agency identifies enhanced oil recovery as a technology pathway for extracting additional resources from existing fields. Biodegradability adds commercial relevance where discharge restrictions or environmental permitting create a cost for conventional surfactant selection. The operational implication is clear: suppliers must demonstrate compatibility with reservoir chemistry and field handling, rather than relying on biodegradability as a stand-alone selling point. ^{[3]International Energy Agency (IEA), Enhanced Oil Recovery Technology Assessment, iea.org}

Personal care demand expands the addressable market through formulation substitution rather than bulk volume alone. Rhamnolipids can serve as mild surfactants and emulsification aids in water-based systems, where their sensory and stability performance must be assessed alongside cost. Evonik's Slovakia output is directed to cleaning, beauty, and personal care applications, giving formulators a scaled commercial reference for this use case. The segment favors liquid formats and higher-purity material because batch consistency and impurity management influence finished-product acceptance. That mix raises the value of technical service and downstream processing capability.

Environmental requirements create the broadest driver because they apply across multiple end uses. EU chemicals policy under REACH governs the registration, evaluation, authorization, and restriction of chemical substances, while the European Green Deal frames the region's transition toward a resource-efficient economy. In the U.S., EPA's Safer Choice program evaluates products against criteria that include safer chemical ingredients. These frameworks do not automatically prescribe rhamnolipids, but they strengthen the commercial case for formulations that can substantiate biodegradability and lower-hazard positioning. The second-order effect is a shift in procurement criteria: sustainability documentation becomes part of supplier qualification, not merely a marketing attribute. ^{[4]European Commission, REACH Regulation and the European Green Deal, ec.europa.eu}

Key Restraints

Rhamnolipid production remains more complex than conventional petrochemical surfactant production. Fermentation requires controlled biological conversion, and commercial material then requires extraction, purification, and formulation. The result is a delivered-cost premium that narrows adoption in high-volume applications where formulation performance does not offset price. Scale can improve utilization of fixed assets and reduce unit processing burden, but it cannot make every commodity surfactant application economically accessible within the forecast period. Suppliers therefore face a portfolio decision: pursue technical-grade volume markets or preserve margins in applications where functional differentiation is paid for.

Feedstock exposure is a parallel restraint. Sugar, vegetable-oil, glycerol, and other carbohydrate inputs link rhamnolipid economics to agricultural commodity cycles and to competing demand from food, fuel, and biochemical markets. The Food and Agriculture Organization tracks agricultural commodity conditions and their implications for food and agricultural supply chains. Production regions with feedstock access and established fermentation infrastructure can respond more effectively to input volatility than import-dependent markets. This favors China, Europe, and North America as supply bases, while raising the commercial risk of rapid capacity replication elsewhere.

Qualification time delays revenue even after production capacity becomes available. Oilfield users need evidence that a biosurfactant works with their water chemistry, equipment, and permitting requirements. Pharmaceutical and healthcare applications face stricter purity and documentation requirements because rhamnolipids may function in biocompatible delivery architectures. The World Health Organization recognizes the importance of technology and innovation in health products, but commercial adoption still depends on application-specific validation. The restraint is operational rather than conceptual: a promising molecular profile does not shorten a customer's qualification protocol.

Industrial Rhamnolipid Market Segment Analysis

By Type

Mono-rhamnolipids generated USD 282.3 million in 2025 and accounted for 60.4% of market value. Their 7.8% CAGR reflects their role as the workhorse type for oilfield chemistry, industrial cleaning, and environmental applications, where surface activity, solubility, and cost-to-performance balance matter. Their molecular structure contains one rhamnose unit, supporting broad use in technical-grade liquid and powder formulations. Mono-rhamnolipids therefore remain closely tied to the liquid, technical-grade, and oil-and-gas segments that dominate current demand.

Di-rhamnolipids generated USD 185.5 million in 2025 and will expand at a faster 9.1% CAGR. Two rhamnose units can support stronger emulsification stability and durability in more demanding chemical environments. This makes the type more relevant to high-specification cosmetics, pharmaceutical delivery, and specialized oilfield formulations. The strategic implication is a market split between mono-rhamnolipids optimized for scalable industrial deployment and di-rhamnolipids optimized for performance-sensitive uses that can support higher purification costs.

By Form

Liquid rhamnolipids accounted for USD 330.3 million, or 70.6% of 2025 revenue, and will grow at an 8.1% CAGR. Ready-to-use products fit smaller-volume users that prioritize handling convenience; concentrates reduce freight and storage burdens for high-throughput customers; aqueous suspensions address specialized rheology and blending needs. In continuous oilfield dosing, industrial cleaning, and water-based personal care manufacture, the ability to meter a liquid directly into an existing system has commercial value. The liquid format consequently links product design to plant operations rather than to chemistry alone.

Powder products represented USD 137.5 million in 2025 and will grow at an 8.9% CAGR. Spray-dried products are the principal broad-use powder format, bulk industrial powders serve transport and storage requirements, and freeze-dried products align with high-purity specialty applications. Powder reduces shipped water and can improve shelf-life management, which supports agricultural bio-adjuvants and dry-blend formulations. The faster powder outlook reflects logistics and dosing advantages, not displacement of liquid products. Suppliers need both forms because end-user handling infrastructure determines the practical product choice.

By Grade

Technical grade 85–90% rhamnolipids held 67.3% share and generated USD 314.9 million in 2025. The grade will grow at an 8.1% CAGR because it serves high-volume, price-sensitive applications including EOR, industrial and institutional cleaning, agriculture, and environmental remediation. Its commercial appeal lies in accepting the composition typical of fermentation-derived material while delivering fit-for-purpose surface-active performance. This grade benefits most directly when large-scale fermentation reduces unit cost.

High purity grade 90–95% generated USD 78.0 million in 2025 and will expand at 9.3%, the fastest grade-level CAGR. Cosmetics and specialized industrial formulations require tighter control over impurities and consistency, so the segment values downstream processing as much as fermentation output. Ultra-high purity material above 95% generated USD 74.9 million and will grow at 8.4%, supported by pharmaceutical and advanced biotechnology applications. The grade structure shows why market value cannot be understood through tonnage alone: purification capability determines access to the smallest but most specification-intensive demand pools.

By End-Use

Oil and gas generated USD 188.1 million in 2025 and accounted for 40.2% of market value. The 8.0% CAGR reflects continued use in EOR, drilling fluids, and well-treatment chemistry, where interfacial-tension reduction and environmental performance are commercially relevant. The segment anchors demand for technical-grade, liquid products, especially in the U.S., China, Saudi Arabia, the UAE, and Brazil. Its size provides a base-load opportunity for producers, but field qualification keeps conversion cycles longer than in many formulated consumer products.

Agriculture generated USD 95.7 million in 2025 and will grow at 9.1%. Rhamnolipids can operate as bio-adjuvants, soil conditioners, biopesticide synergists, and plant-defense elicitors, creating a multi-function value proposition rather than a single surfactant role. India, Brazil, and Mexico provide the core growth geographies. Agricultural demand also favors powder products where dry mixing and transport efficiency matter, connecting the fastest-growing end-use segment to the faster-growing form segment. ^{[6]Food and Agriculture Organization of the United Nations (FAO), Sustainable Agriculture and Bio-Based Inputs Resources, fao.org}

Pharmaceuticals and healthcare generated USD 76.0 million in 2025 and will grow at 8.8%. Rhamnolipids' amphiphilic behavior makes them relevant to emulsification, encapsulation, and nanoparticle-oriented drug delivery research. Cosmetics and personal care generated USD 75.8 million and will grow at 8.1%, supported by mild-surfactant and clean-formulation positioning. The others category, including textiles, household and industrial cleaners, and bioremediation, generated USD 32.3 million and will grow at 7.8%. Each of these uses depends on a different purchasing logic, which makes application support a central route to competitive differentiation. ^{[7]World Health Organization (WHO), Innovation in Drug Delivery Systems, who.int}

Industrial Rhamnolipid Market Regional Analysis

Asia Pacific

Asia Pacific is the largest market, generating USD 162.1 million in 2025 and growing at an 8.9% CAGR through 2035. China combines fermentation supply capability with demand from EOR and industrial cleaning, generating USD 61.6 million in 2025. India generated USD 16.2 million and will grow at 9.8%, supported by agricultural bio-adjuvants and pharmaceutical manufacturing. Japan, South Korea, and Australia add demand in cosmetics, advanced cleaning, and pharmaceutical applications. The regional advantage comes from the interaction of feedstock access, fermentation infrastructure, and broad industrial demand; the constraint remains the need to maintain consistent quality as producers expand export channels.

North America

North America generated USD 132.9 million in 2025 and held 28.4% share. The U.S. accounted for USD 109.6 million, supported by EOR, industrial and institutional cleaning, and personal care formulation. EPA Safer Choice provides a recognized framework for evaluating safer chemical ingredients in consumer and institutional products. Canada complements the U.S. base through oil-sands-related recovery applications and food-processing and cleaning demand. The region will grow at 7.6%, its slower rate reflecting a larger existing base and mature customer qualification practices rather than weak underlying demand. ^{[5]U.S. Environmental Protection Agency (EPA), Safer Choice Program, epa.gov}

Europe

Europe generated USD 110.9 million in 2025 and will grow at 7.8%. Germany generated USD 31.1 million, benefiting from its concentration of specialty chemical formulators and proximity to Evonik's Slovakia supply base. The UK, France, Spain, and Italy provide demand across personal care, agriculture, and industrial cleaning. REACH and the European Green Deal reinforce formulation interest in bio-based alternatives. Europe therefore has a compliance-led demand case and a localized-scale-supply advantage, although formulators still face the price and validation requirements attached to material substitution.

Latin America

Latin America generated USD 36.3 million in 2025, held 7.8% share, and is the fastest-growing region at 9.5%. Brazil generated USD 18.1 million, driven by EOR activity, agriculture, and environmental applications. Mexico and Argentina extend the agricultural and biotechnology demand base. The region's growth rests on end-use expansion, but suppliers must account for distribution coverage and local technical support rather than assuming that strong demand automatically converts into sales.

Middle East and Africa

The Middle East and Africa generated USD 25.7 million and held 5.5% share in 2025. The region will grow at 9.3%, led by EOR-related demand in Saudi Arabia and the UAE, alongside environmental remediation and specialty chemical distribution in South Africa. Oilfield applications provide a clear use case, but feedstock dependence and a less established local fermentation base constrain regional manufacturing depth. The near-term market will therefore remain more dependent on imported material and distributor capability than the major production hubs.

Industrial Rhamnolipid Market Share & Competitive Landscape

Evonik Industries AG leads the market with an estimated 12% share, while the top five suppliers collectively hold 43%. This structure indicates moderate fragmentation: the leader holds a clear scale advantage, but a large residual market remains available to regional specialists and application-focused producers. The HHI calculation using the individual top-five estimates and the residual category yields approximately 2,256, indicating moderate concentration. Because private-company shares are estimates, this calculation is directional rather than a competition-law market definition.

Evonik's competitive position rests on its industrial-scale Slovakia plant and the REWOFERM RL product range for cleaning, beauty, and personal care applications. The company has converted a technology-scale argument into a supply-scale argument, which matters for customers seeking a supplier capable of supporting multi-market formulation programs. Stepan Company competes through an established surfactant platform and the STEPANGREEN rhamnolipid range, giving it a commercial bridge into existing personal care and cleaning accounts. AGAE Technologies LLC competes through fermentation specialization and high-purity rhamnolipid capabilities; Chemical & Engineering News reported in March 2025 that its Asian facility had reached full-scale production with capacity above 1,000 metric tons per year. ^{[8]Stepan Company, STEPANGREEN® Rhamnolipid Product Information, stepan.com}

Jeneil Biotech Inc brings a long-established fermentation and product-supply position through its JBR portfolio, including mono- and di-rhamnolipid products. Holiferm Ltd remains in the competitive scope, but its position requires conditional treatment: Chemical & Engineering News reported in March 2024 that the company was no longer making rhamnolipids. Its inclusion should therefore be read as a competitive-scope designation rather than confirmation of current production status. This disclosure is material because supplier status directly affects market-share and supply-capacity interpretation.

Major players operating in the industrial rhamnolipid market include Evonik Industries AG, Stepan Company, AGAE Technologies LLC, Jeneil Biotech Inc, GlycoSurf, Zhejiang Silver Elephant Bio-engineering Co. Ltd, Shaanxi Deguan Biotechnology Co. Ltd, Holiferm Ltd, Seebio Biotech (Shanghai) Co., Ltd., Starchem Enterprises Limited, and Xi'an Rege Biotechnology Co., Ltd. Zhejiang Silver Elephant and Shaanxi Deguan strengthen the Chinese supply base in technical and application-oriented grades. GlycoSurf operates as a specialty biosurfactant developer. Seebio offers pharmaceutical-grade and petroleum/agricultural rhamnolipid product lines. Starchem supplies 80% and 95% glycolipid grades for industrial end uses. Xi'an Rege adds a dedicated rhamnolipid supplier profile across cleaning, oilfield, and agricultural uses.

Recent Industry Developments

Mar 2025: Chemical & Engineering News reported that AGAE Technologies' Asian biosurfactant facility reached full-scale production, with capacity above 1,000 metric tons per year. The development increases the strategic importance of fermentation scale in an Asia Pacific market already defined by manufacturing depth.

May 2024: Evonik inaugurated its industrial-scale rhamnolipid plant in Slovenská Ľupča, Slovakia. The facility establishes a scaled European supply reference for cleaning, beauty, and personal care formulators.

Mar 2024: Chemical & Engineering News reported that Holiferm was no longer making rhamnolipids. The statement requires conditional treatment of Holiferm's competitive profile and prevents its position from being interpreted as verified active production.